Skip to main content
OpenTrials
Completed

NCT Number: NCT06661616

Cognitive Effects Associated With Hippocampal Neurogenesis Induced by ECT in the Treatment of Depression

Electroconvulsive therapy (ECT) is the treatment of choice for drug-resistant depression (30% of patients), or when there is a short-term risk to the patient's life. Despite its robust efficacy and rapid onset of action, its use is limited both by the limited range of treatment available and by the cognitive effects sometimes induced. The present study focuses on the links between the efficacy of ECT, its cognitive effects and the formation of new neurons in the hippocampus (hippocampal neurogenesis) associated with this treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sainte-Anne Hospital (GHU Paris Psychiatrie et Neurosciences)

Paris, 75014, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Study population: depressed subjects treated with ECT
  • Male or female over 18 years of age
  • Hospitalised at the Centre Hospitalier Sainte-Anne
  • Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
  • Indication for ECT treatment
  • Patient has given informed written consent
  • Beneficiary of a social security scheme
  • Control population: depressed subjects treated without ECT
  • Male or female over 18 years of age
  • Hospitalised at the Centre Hospitalier Sainte-Anne
  • Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
  • Patient who has given informed written consent
  • Beneficiary of a social security scheme
  • Control population: healthy volunteers
  • Male or female over 18 years of age
  • Patient with written informed consent
  • Beneficiary of a social security scheme

Exclusion criteria

  • Study population: depressed subjects with ECT
  • Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on a substance other than tobacco
  • Neurological comorbidity: Parkinson's disease, dementia
  • ECT treatment in the 6 months prior to inclusion
  • Compulsory care
  • Protected adults, persons under court protection measures
  • Persons deprived of liberty by judicial or administrative decision;
  • Refusal of consent to ECT treatment
  • Contraindications to ECT (HTIC, recent history of stroke, severe uncontrolled arterial hypertension, contraindication to anaesthesia)
  • Contraindications to MRI (patients with metal prostheses, claustrophobia)
  • Pregnant or breast-feeding women
  • Control population: depressed subjects without ECT
  • Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on any substance other than tobacco
  • Neurological comorbidity: Parkinson's disease, dementia
  • ECT treatment in the 6 months prior to inclusion
  • Compulsory care
  • Protected adults, persons under court protection measures
  • Persons deprived of liberty by judicial or administrative decision;
  • Pregnant or breast-feeding women
  • Control population: healthyvolunteers
  • Protected adults, persons under legal protection,
  • Persons deprived of their liberty by judicial or administrative decision ;
  • persons hospitalised for purposes other than research
  • Clear psychiatric history
  • Dependence on any substance other than tobacco
  • Neurological history: Parkinson's disease, dementia
  • Pregnant or breast-feeding women

Treatment and study plan

Primary outcomes

  1. Correlation between increased hippocampal volume and post-ECT retrograde amnesia

    Time frame: After a course of ECT, up to 3 months

Sponsors and collaborators

Lead sponsor

Centre Hospitalier St Anne

Other

Registry information

Official study title

Cognitive Effects Associated With Hippocampal Neurogenesis Induced by Electroconvulsive Therapy in the Treatment of Depression

Acronym: CONHECT

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Oct 28, 2024
Registry last updated
Oct 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.